ViroCure

RC402

A naturally occuring reovirus originally isolated from a healthy child, which pre-clinical studies have shown to be highly effective at fighting metastatic tumors (RC402).

​

• Proven to be long-lasting, safe, & stable for human subjects

• Improved cytopathic effect without additional arming in select tumor types

• Anti-angiogenic effect to kill tumors

• Applicable for both local and systemic administration

• Usage patent granted in Korea, China, & Japan

• Clinical trial scheduled in Australia in 2019 for liver-metastasized solid tumors

• Targets cancers prevalent in China

RP116

A naturally occuring reovirus which preliminary research has shown to be highly effective at fighting oral cancers, salivary gland cancer, soft tissue sarcoma, melanoma, etc. (RP116)

​

• First-in-the-world, proprietary oncolytic virus with modification of sigma1, a major immunogenic capsid protein of RC402​​

• Systemic administration with a potent tumor killing activity

• Applicable to immuno-competent and compromised tumor patients, e.g. pregnant women, children, AIDS patients, etc.

• Patents granted in the USA / Challenge to global market

MC509

A naturally occuring rabbit-specific poxvirus, originally isolated from a Brazillian rabbit species. Not known to cause diseases outside of rabbit species. In pre-clinical studies, MC509 has been highly oncolytic against tumor-bearing animals. 

​

• Different backbone from other viruses

  • Systemic administration possible without generating neutralizing antibodies

• Using gene editing to create new viral agents

  • Manipulation of tumor micro-environment for immune evasion, boosting, etc.

  • Creation of cancer vaccines

• Targets global pharma for licensing-out & partnership

SC717

A naturally occuring squirrel-specific poxvirus originally isolated from a grey squirrel. Not known to cause diseases outside of squirrel species. In pre-clinical studies, SC717 has been highly oncolytic against tumor-bearing animals.

​

• Oncolytic viral activity discovered and patented by Virocure

• Systemic administration possible without generating neutralising antibody

• Using gene editing to create new viral agents

  • Manipulation of tumor micro-environment for immune evasion, boosting, etc.

  • Creation of cancer vaccines

• Targeting global pharma for licensing-out & partnership